HC Wainwright announced Lipocine Inc (NASDAQ:LPCN), bumping up its stock price target to $25.00 today
- Updated: October 17, 2016
In a report released on 10/17/2016 HC Wainwright increased the stock price target of Lipocine Inc (NASDAQ:LPCN) to $25.00 reporting a possible upside of 5.85%.
Previously on 10/7/2016, HC Wainwright reported on Lipocine Inc (NASDAQ:LPCN) increased the target price from $0.00 to $25.00. At the time, this indicated a possible upside of 5.00%.
Just yesterday Lipocine Inc (NASDAQ:LPCN) traded -3.95% lower at $3.65. Lipocine Inc’s 50-day moving average is $3.95 and its 200-day moving average is $6.23. The last closing price is down -41.42% from the 200-day moving average, compared to the Standard & Poor's 500 Index which has decreased -0.01% over the same time period. 1,023,940 shares of LPCN traded hands, up from an average trading volume of 514,095
Recent Performance Chart
Lipocine Inc has 52 week low of $2.51 and a 52 week high of $14.80 and has a market capitalization of $0.
Brief Synopsis On Lipocine Inc (NASDAQ:LPCN)
Lipocine Inc. is a specialty pharmaceutical company. The Company is focused on applying its oral drug delivery technology for the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for bioavailable drugs. Its lead product candidate, LPCN 1021, is an oral testosterone replacement therapy (TRT), designed for twice-a-day dosing and is in Phase III testing. The Company's additional pipeline candidates include LPCN 1111, an oral testosterone therapy product targeted for once daily dosing, which is in Phase II testing, and LPCN 1107, an oral therapy for the prevention of preterm birth, which is in Phase I testing. These products are based on its Lip'ral promicellar drug delivery technology platform. Lip'ral promicellar technology is a technology based on lipidic compositions, which form an optimal dispersed phase in the gastrointestinal environment for improved absorption of insoluble drugs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.